Welcome to our dedicated page for ORGANON & news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & stock.
Organon & Co. reports developments as a global healthcare company with portfolios in Women's Health and General Medicines, including biosimilars. Company news commonly covers operating results, product and regulatory updates, and clinical data for medicines such as VTAMA cream for atopic dermatitis and plaque psoriasis, biosimilar approvals including POHERDY, and established women's health brands and devices such as Nexplanon, Follistim, and Jada.
Updates also address capital-structure disclosures, governance matters, shareholder voting topics, and material agreements, alongside the company's commercial activity across more than 140 markets.
Organon (NYSE: OGN) and ObsEva (NASDAQ: OBSV) have announced a licensing agreement for ebopiprant (OBE022), an investigational drug aimed at treating preterm labor. This agreement allows Organon exclusive global development and commercialization rights for ebopiprant, which could fill a critical gap in acute preterm labor treatment in the U.S. ObsEva will receive up to $500 million, including $25 million at signing, and tiered royalties on sales. The drug shows promise based on Phase 2a trial results, which indicated a significant reduction in preterm deliveries.
Organon (NYSE: OGN) is set to release its Q2 2021 financial results on August 12, 2021, prior to a conference call at 8:30 a.m. ET. Interested parties can access the live call via webcast. Following the call, a replay will be available on the company’s website. Organon focuses on women's health with over 60 products, including a strong reproductive health portfolio and expanding biosimilars business, supported by strong cash flows. The company aims for growth through acquisitions and collaborations in international markets.
Organon (NYSE: OGN) has received an unsolicited mini-tender offer from TRC Capital Investment Corporation, seeking to buy up to 3 million shares (1.18% of outstanding shares) at $28.63 each. This price is approximately 4.5% lower than Organon's last closing price of $29.98 on June 18, 2021. Organon recommends that stockholders reject the offer as it is below market value and subject to conditions. TRC's offer does not provide the same protections as larger tender offers, and investors are urged to consult market quotes and their advisors.
Organon (NYSE: OGN) has filed its Form 10-Q for Q1 2021, detailing financial results as a Merck spinoff. The financial statements abide by GAAP but do not represent the company's standalone financial condition. The company reaffirms its 2021 guidance, expecting revenue between $6.1 billion and $6.4 billion and an Adjusted EBITDA margin of 36.0% to 38.0%. Organon will report Q2 results on August 12, 2021, alongside its first standalone earnings call. The company focuses on women's health with a robust portfolio and aims to leverage growth opportunities globally.
Organon (NYSE: OGN) has successfully completed its acquisition of Alydia Health, a medical device company dedicated to preventing maternal morbidity and mortality due to postpartum hemorrhage (PPH). The acquisition, valued at $240 million, strengthens Organon's commitment to addressing women's healthcare needs. Alydia's Jada® System, which promotes uterine contraction to reduce excessive bleeding post-childbirth, received FDA marketing authorization in 2020. This strategic move expands Organon's portfolio into the medical device sector, enhancing its presence in reproductive health.
Organon (NYSE: OGN) celebrates its launch as a global women's health company with an opening bell ceremony at the NYSE. The company focuses on addressing women's health needs, emphasizing reproductive health and unique health issues. Organon's portfolio includes over 60 products across 140 markets, generating approximately $6.5 billion annually, with 80% from outside the U.S. Key growth areas include Women’s Health, Biosimilars, and Established Brands. The firm aims to enhance women's health through innovation and has a majority female board to guide its mission.